ASPC 2020 Virtual Summit on CVD Prevention

 

ASPC 2020 Virtual Summit on CVD Prevention
A

Apolipoprotein B & CVD Risk: How Can We Improve CVD Prevention With a Long-Term apoB Model? What Are the Benefits/Value of apoB? Why There Is apoB Resistance in the US vs. Europe?

By ASPC 2020 Virtual Summit on CVD Prevention FEATURING Allan Sniderman
By ASPC 2020 Virtual Summit on CVD Prevention FEATURING Allan Sniderman
361 views
March 16, 2021
Comments 1
Login to view comments. Click here to Login

Featured Video

02:17
Novartis Cardiology

Understanding Acquisition and Billing for a Non-Statin Lipid-Lowerin…

Feat. B. Buell

Featured Video

10:56
Novartis Cardiology

Expert Insights on Pivotal Phase 3 and Long-term Trial Data in Prima…

Feat. D. G. Karalis, M. Myerson
Videos
35:56

Integrating Imaging & Advanced Blood Testing for CVD Prevention/Mana…

ASPC 2020 Virtual Summit on CVD Prevention

A. Agatston

483 views
08:09

Implementation of FIND FH Into Clinical Care at Penn Medicine: Can M…

ASPC 2020 Virtual Summit on CVD Prevention

S. Sheth

7 views
05:37

Lessons Learned from the ISCHEMIA Trial: How to Diagnose/Manage CAD …

ASPC 2020 Virtual Summit on CVD Prevention

D. Maron

391 views
11:29

Managing Patients With Stable CAD: When to Consider the Cath Lab? Wh…

ASPC 2020 Virtual Summit on CVD Prevention

D. Maron

1.3K views
21:16

ASPC Expert Discussion on Biologics Usage for CV Risk Reduction, Eff…

ASPC 2020 Virtual Summit on CVD Prevention

C. Ballantyne, A. Marie Navar, D. Maron, K. Ferdinand, P. Ridker

37 views
07:35

Continuity of Care for Patients With/At High Risk for CVD During COV…

ASPC 2020 Virtual Summit on CVD Prevention

A. Khera

89 views
08:31

Management of HF With Preserved Ejection Fraction: How Can We Preven…

ASPC 2020 Virtual Summit on CVD Prevention

D. Schocken

132 views
18:46

How Can We Prevent the Majority of CV Events? What Are the Milion He…

ASPC 2020 Virtual Summit on CVD Prevention

L. Sperling

349 views
19:17

NIH Scientific Approach to Inclusive Excellence: Why Diversity Matte…

ASPC 2020 Virtual Summit on CVD Prevention

H. A. Valantine

8 views
10:53

ASPC CVD Prevention Panel Discussion: How Can We Educate Our Patient…

ASPC 2020 Virtual Summit on CVD Prevention

L. Shaw, N. Wenger, V. Taqueti, R. Bullock-Palmer, E. Michos, M. Gulati, P. Taub

18 views
05:07

Expert Discussion on Transdermal Hormone Replacement Therapy & How t…

ASPC 2020 Virtual Summit on CVD Prevention

L. Shaw, N. Wenger, V. Taqueti, R. Bullock-Palmer, E. Michos, M. Gulati, P. Taub

16 views
12:41

Disparities in the Use of Preventive Medications and Risk Factor Con…

ASPC 2020 Virtual Summit on CVD Prevention

K. Vu

9 views
27:57

100 Years from C-Reactive Protein to Anti-Inflammatory Therapy for A…

ASPC 2020 Virtual Summit on CVD Prevention

P. Ridker

60 views
28:45

Apolipoprotein B & CVD Risk: How Can We Improve CVD Prevention With …

ASPC 2020 Virtual Summit on CVD Prevention

A. Sniderman

361 views
32:07

Adverse Pregnancy Outcomes & CVD Risk: What Are the Risks and How to…

ASPC 2020 Virtual Summit on CVD Prevention

R. Bullock-Palmer

07:13

FH Visual Aids in Patient Education Research Highlights: Can Distrib…

ASPC 2020 Virtual Summit on CVD Prevention

D. M. Harmon

16 views
05:51

HF With Preserved Ejection Fraction: How to Distinguish HFrEF & HFpE…

ASPC 2020 Virtual Summit on CVD Prevention

D. Schocken

20 views
15:01

Diagnosis/Management of CMD: How to Use Novel Imaging Tools to Under…

ASPC 2020 Virtual Summit on CVD Prevention

V. Taqueti

16 views
27:34

Atherosclerosis & MicroRNAs: How MicroRNAs Impacts Risk for Atheroge…

ASPC 2020 Virtual Summit on CVD Prevention

P. Toth

94 views
37:24

Primary Prevention by CAC vs. CTA: Which One Is Better and Why? - SC…

ASPC 2020 Virtual Summit on CVD Prevention

J. Min, K. Nasir

38 views
47:06

Jackson Heart Study Overview: Racial Disparity Trends, Risk Assessme…

ASPC 2020 Virtual Summit on CVD Prevention

H. Taylor

13 views
19:28

ASPC Panel Discussion on CV Risk Prevention With Nutrition, Hyperten…

ASPC 2020 Virtual Summit on CVD Prevention

K. Ferdinand, D. Maron, L. Sperling, I. Pina, H. Taylor

18 views
20:21

Discussion on CTA/CAC for Primary Prevention, Genetic Testing, LDL M…

ASPC 2020 Virtual Summit on CVD Prevention

R. Blankstein, S. Virani, A. Agatston, J. Min, S. Sheth, K. Nasir, A. Khera

24 views
28:23

New Insights Into Assessing Risk for Hispanic Patients: Why it Is Im…

ASPC 2020 Virtual Summit on CVD Prevention

I. Pina

11 views
16:33

Menopause and Its Impact on Women's CVD Health: How to Assess Risk F…

ASPC 2020 Virtual Summit on CVD Prevention

E. Michos

485 views
14:00

Genetic Testing in Preventive Cardiology: Are Those With FH Mutation…

ASPC 2020 Virtual Summit on CVD Prevention

A. Khera

356 views
14:55

Statin Usage in Athletes: Is There Increased Muscle Injury With Stat…

ASPC 2020 Virtual Summit on CVD Prevention

P. D. Thompson

22 views
27:36

Sex Differences in Atherosclerosis: Is There a Sex Specific Phenotyp…

ASPC 2020 Virtual Summit on CVD Prevention

L. Shaw

29 views
16:05

Polypill for CVD Prevention: When Is Polypharmacy Appropriate? Can R…

ASPC 2020 Virtual Summit on CVD Prevention

K. Ferdinand

164 views
28:02

CVD Prevention for Women: What Are the Unique/Predominant Risk Facto…

ASPC 2020 Virtual Summit on CVD Prevention

N. Wenger

17 views